Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alder Biopharmaceuticals has entered into a broad collaborative alliance with Schering-Plough aimed at the identification and manufacture of antibody therapeutics.
Subscribe to our email newsletter
The collaboration will use Alder’s proprietary yeast production system and high throughput antibody selection system to identify and produce antibodies.
Under terms of the agreement, Alder will work on up to ten Schering-Plough antibody products. Schering-Plough will provide either the antibody sequence or the antigen and Alder will provide a unique proprietary antibody expressing strain or, in the case of the selection system, both the antibody and the strain.
For each of the ten therapeutic products developed under the alliance, Alder is eligible to receive milestone payments related to successful advancement, research support, and future royalties on sales of resulting products.
“This further validates the vast potential of Alder’s proprietary antibody technologies,” said Dr Randall Schatzman, president and CEO of Alder.